Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

Effectiveness of the proposed method to decrease chloroplast contamination. by Gabriela Madrid (11871401)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

The flexural lumber properties of Pinus patula Schiede ex Schltdl. & Cham. improve with decreasing initial tree spacing by Justin Erasmus (8702619)

“…After accounting for ring width differences, there remained a significant effect of initial spacing on the parameters of models predicting microfibril angle and wood density.…”

JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i> by Rayane Brinck Teixeira (6676529)

Thymus regeneration promotes naïve T-cell recovery in iMycTg aging-E mice and a partial decrease in Treg frequencies. by Abigail Morales-Sánchez (21799582)

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. by Francesca Catto (21253435)

“…<p>(A) Each 3-dimensional map of statistically affected voxels (p < 0.05, with the red scale, representing the significance in decrease of microglia, and the cyan scale, representing the increase in microglia; reference atlas is grey) summarizes all the treated and control samples within a cohort (3 samples per group). …”

Significant associations in GWAS. by Dai Nogimura (21445649)

Subjects:

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Therapeutic drug monitoring should be performed in vulnerable populations, such as the elderly, children, and infants, to improve efficacy and reduce toxicity. Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. …”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Therapeutic drug monitoring should be performed in vulnerable populations, such as the elderly, children, and infants, to improve efficacy and reduce toxicity. Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. …”

miRNA 221 improved left ventricular contractile function in MIRI mice. by Hongyu Li (1332669)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

DALY and HLY in Portugal, 1990–2019. The first graph shows a decreasing trend of DALY and the second graph shows an increasing trend of HLY. by Aida Isabel Tavares (12080156)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Deletion of C3 and C3aR reversed <i>S. aureus</i>-induced decrease in synapse density and increase in microglial phagocytosis of synapses. by Haifang Zhang (314544)